Albireo Pharma, Inc is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 90 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Albireo Pharma
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALBO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Albireo Pharma stock price (NASDAQ: ALBO)Use our graph to track the performance of ALBO stocks over time.
Albireo Pharma shares at a glance
|Latest market close||$33.45|
|52-week range||$22.78 - $43.44|
|50-day moving average||$33.93|
|200-day moving average||$34.40|
|Wall St. target price||$73.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.23|
Buy Albireo Pharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Albireo Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Albireo Pharma price performance over time
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||-3.99%|
|3 months (2021-05-04)||10.14%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Albireo Pharma financials
|Revenue TTM||$8.7 million|
|Gross profit TTM||$8.3 million|
|Return on assets TTM||-30.82%|
|Return on equity TTM||-91.74%|
|Market capitalisation||$561.4 million|
TTM: trailing 12 months
Shorting Albireo Pharma shares
There are currently 1.6 million Albireo Pharma shares held short by investors – that's known as Albireo Pharma's "short interest". This figure is 0.8% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Albireo Pharma shares can be evaluated.
Albireo Pharma's "short interest ratio" (SIR)
Albireo Pharma's "short interest ratio" (SIR) is the quantity of Albireo Pharma shares currently shorted divided by the average quantity of Albireo Pharma shares traded daily (recently around 200502.73631841). Albireo Pharma's SIR currently stands at 8.04. In other words for every 100,000 Albireo Pharma shares traded daily on the market, roughly 8040 shares are currently held short.
However Albireo Pharma's short interest can also be evaluated against the total number of Albireo Pharma shares, or, against the total number of tradable Albireo Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Albireo Pharma's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Albireo Pharma shares in existence, roughly 80 shares are currently held short) or 0.0964% of the tradable shares (for every 100,000 tradable Albireo Pharma shares, roughly 96 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Albireo Pharma.
Find out more about how you can short Albireo Pharma stock.
Albireo Pharma share dividends
We're not expecting Albireo Pharma to pay a dividend over the next 12 months.
Have Albireo Pharma's shares ever split?
Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.
Albireo Pharma share price volatility
Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $22.78 up to $43.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 1.5278. This would suggest that Albireo Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Albireo Pharma overview
Albireo Pharma, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.
Stocks similar to Albireo Pharma
Albireo Pharma in the news
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
Albireo Pharma removed from Best Ideas List at Wedbush
Frequently asked questionsWhat percentage of Albireo Pharma is owned by insiders or institutions?
Currently 0.657% of Albireo Pharma shares are held by insiders and 94.686% by institutions. How many people work for Albireo Pharma?
Latest data suggests 90 work at Albireo Pharma. When does the fiscal year end for Albireo Pharma?
Albireo Pharma's fiscal year ends in December. Where is Albireo Pharma based?
Albireo Pharma's address is: 10 Post Office Square, Boston, MA, United States, 02109 What is Albireo Pharma's ISIN number?
Albireo Pharma's international securities identification number is: US01345P1066 What is Albireo Pharma's CUSIP number?
Albireo Pharma's Committee on Uniform Securities Identification Procedures number is: 01345P106
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert